|Sorrento Therapeutics, Inc.|
6042 Cornerstone Ct. West
United States - Map
Sorrento Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary drug therapeutics for addressing unmet medical needs in the United States, Europe, and internationally. The company primary therapeutic focus is oncology, including the treatment of chronic cancer pain, as well as developing therapeutic products for other indications, such as immunology and infectious diseases. Its lead product, Cynviloq, is polymeric, albumin-free nanoparticle paclitaxel formulation, approved and marketed in South Korea for metastatic breast cancer (MBC), non-small cell lung cancer (NSCLC), and ovarian cancer under the trade name Genexol-PM. Cynviloq has also completed Phase I, Phase II, and Phase III clinical trials, and post-marketing surveillance studies in MBC, NSCLC, ovarian, pancreatic, and bladder cancer. The company is also developing resiniferatoxin, a non-opiate, ultra potent, and selective agonist of the TRPV-1 receptor for intractable pain in end-stage disease. In addition, the companys preclinical human therapeutic monoclonal antibodies include human anti- PD-L1 and anti-PD-1 checkpoint inhibitors; antibody drug conjugates; and bispecific antibodies, as well as Chimeric Antigen Receptor Tumor-attacking Neukoplast for adoptive cellular immunotherapies. It has a collaboration agreement with Conkwest Incorporated to generate and develop products for adoptive immunocellular therapy utilizing Neukoplast cells and chimeric antigen receptors; and NantWorks, Inc. to develop anti-cancer immunotherapies. Sorrento Therapeutics, Inc. was founded in 2006 and is headquartered in San Diego, California.
|Dr. Henry H. Ji Ph.D.,
Co-Founder, Chief Exec. Officer, Pres and Director
|Mr. George Uy ,
Chief Commercial Officer and Exec. VP
|Dr. Michael A. Royal M.D., J.D., MBA,
Exec. VP of Clinical and Regulatory Affairs
|Mr. Douglas J. Langston ,
VP of Fin.
|Mr. George K. Ng Esq.,
Chief Legal Officer and Exec. VP
|Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|